(Q30248803)

13 June 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance (English)

1 reference

13 June 2017

1 reference

1 reference

1 reference

David R Owens

1

1 reference

13 June 2017

language of work or name

English

0 references

publication date

1 August 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

13 June 2017

published in

1 reference

13 June 2017

volume

12

1 reference

13 June 2017

issue

8

1 reference

13 June 2017

page(s)

977-987

1 reference

Distinguishing the economic costs associated with type 1 and type 2 diabetes

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

The past, present, and future of basal insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

A review of the pharmacological properties of insulin degludec and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

The use of U-500 in patients with extreme insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1202916

10.1080/17425255.2016.1202916

21 January 2018

Identifiers

DOI

1 reference

13 June 2017

1 reference